Overview
Stoke Therapeutics Q3 revenue grows to $10.6 mln, beating analyst expectations
Net loss for Q3 2025 was $38.3 mln, compared to $26.4 mln in Q3 2024
Company progressing with Phase 3 EMPEROR study for zorevunersen
Outlook
Stoke plans to complete Phase 3 EMPEROR study enrollment by H2 2026
Company to meet FDA by year-end 2025 for expedited zorevunersen approval
Stoke to activate European sites for STK-002 study in early 2026
Result Drivers
CONTRACTUAL AGREEMENTS - Revenue increase driven by obligations under agreements with Acadia and Biogen
FINANCIAL POSITION - Strong cash reserves allowing investment in business and pipeline expansion
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $10.63 mln | $6.16 mln (10 Analysts) |
Q3 Net Income | -$38.34 mln | ||
Q3 Operating Expenses | $53.72 mln | ||
Q3 Operating Income | -$43.09 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Stoke Therapeutics Inc is $30.00, about 13% above its November 3 closing price of $26.10
Press Release: ID:nBw6Qvycwa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)